Increased Prevalence of Obesity and Glucose Intolerance in Youth Treated with Second

Abstract

French

Objective:

To compare the rates of obesity, impaired fasting glucose (IFG), and type 2 diabetes between second-generation antipsychotic (SGA)-treated and -naive youth.

Methods:

A retrospective chart review was conducted for all child and adolescent psychiatry emergency admissions over 2.5 years. Data collected included age, sex, psychiatric diagnosis, medications, height, weight, fasting glucose, and lipid profile. Body mass index (BMI) was standardized for age and sex and converted to a z score. Overweight was defined as a BMI between the 85th and 95th percentile and obese as a BMI at the 95th percentile or greater for age and sex. The 2007 American Diabetes Association criteria for IFG and type 2 diabetes were used.

Results:

Among the 432 admissions, 167 (39%) had both height and weight measured, and 145 (34%) had fasting glucose measured. The mean zBMI was higher in the SGA-treated (n = 68), compared with the SGA-naive group (n = 99) (mean difference 0.81; 95% CI 0.46 to 1.16). In the SGA-treated group, 31% were obese and 26% were overweight, compared with 15% and 8%, respectively, in the SGA-naive group (P < 0.01). In the SGA-treated group (n = 65), 21.5% had IFG or type 2 diabetes, compared with 7.5% in the SGA-naive group (n = 80) (P = 0.01).

Conclusions:

Youth treated with SGAs have significantly higher rates of obesity and glucose intolerance than SGA-naive youth. These data emphasize the need for consistent metabolic monitoring of youth with psychiatric disorders who are prescribed SGAs.

Keywords

second-generation antipsychotics youth glucose intolerance obesity metabolic monitoring

References

Waddell

Shepherd

Prevalence of mental disorders in children and youth [Internet]. Vancouver (BC): The University of British Columbia; 2002 [cited 2009 Oct 14]. Available from: http://www.mcf.gov.bc.ca/mental_health/mh_publications/02a_cymh.pdf.

Dœy

Handelman

Seabrooke

Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry. 2007;52:363–368.

Cooper

Arbogast

Ding

Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6:79–83.

Statistics Canada. BC census data 2002–2006 [Internet]. Ottawa (ON): Statistics Canada; 2008. Available from: http://www.bcstats.gov.bc.ca/census.asp.

Gentile

Long-term treatment with atypical antipsychotics and the risk of weight gain. Drug Saf. 2006;29:303–319.

Wetterling

Bodyweight gain with atypical antipsychotics: A comparative review. Drug Saf. 2001;24:59–74.

Meyer

Koro

. The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophr Res. 2004;70:1–17.

Zhao

Liu

Effects of typical and atypical antitpsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology. 2006;186:572–578.

Nasrallah

Newcomer

. Atypical antipsychotics and metabolic dysregulation—evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;17:173–180.

10.

Cohen

Atypical antipsychotics and new onset diabetes mellitus. Pharmacopsychiatry. 2004;37:1–11.

11.

Henderson

. Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence? CNS Drugs. 2002;16:77–89.

12.

Jin

Meyer

Jest

. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59–64.

13.

Llorente

Urritia

Diabetes, psychiatric disorders, and the metabolic effects of antipsychotic medications. Clin Diabetes. 2006;24:18–24.

14.

Alberti

KGMM

Zimmet

Shaw

. The metabolic syndrome in children and adolescents. Lancet. 2007;369:2059–2061.

15.

Sicras-Mainar

Blanca-Tamayo

Rejas-Gutierrez

Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A cross-sectional assessment of a primary health care database. Eur Psychiatry. 2008;23:100–108.

16.

Bloomgarden

. Atypical antipsychotic agents, retinopathy, nephropathy, and cardiovascular disease. Diabetes Care. 2006;24:1439–1446.

17.

Fedorowicz

Fombonne

Metabolic side effects of atypical antipsychotics in children: A literature review. J Psychopharmacol. 2005;19:533–550.

18.

Correll

. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46:687–700.

19.

Selva

Scott

. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr. 2001;136:9366–9938.

20.

Koller

Malozowski

Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA. 2001;286:2547–2548.

21.

Weiss

Caprio

The metabolic consequences of childhood obesity. Best Pract Res Clin Endocrinol Metab. 2005;19:405–419.

22.

US Department of Health and Human Services. 2000 CDC Growth Charts: United States [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2009 [cited 2007 Nov]. Available from: http://www.cdc.gov/growthcharts.

23.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30(1):S42–S47.

24.

Jolliffe

Janseen

Distribution of lipoproteins by age and gender in adolescents. Circulation. 2006;114:1056–1062.

25.

Falkner

National high blood pressure education program working group on high blood pressure in children and adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–576.

26.

Tremblay

Willms

. Secular trends in the body mass index of Canadian children. CMAJ. 2000;163:1429–1433.

27.

Patel

Kistler

James

A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy. 2004;24:824–830.

28.

Fleischhaker

Heiser

Hennighausen

Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm. 2007;114:273–280.

29.

Ratzoni

Gothelf

Brand-Gothelf

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. 2002;41:337–343.

30.

Krekoukia

Nassis

Psarra

Elevated total and central adiposity and low physical activity are associated with insulin resistance in children. Metab Clin Exp. 2007;56:206–213.

31.

Fagot-Campagna

Saaddine

. Diabetes, impaired fasting glucose, and elevated HbA in US adolescents: The Third National Health and Nutrition Examination Survey. Diabetes Care. 2001;24:834–837.

32.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

33.

Yokoyama

Okudaira

Otani

Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care. 1997;20:844–847.

34.

Krakoff

Lindsay

Looker

Incidence of retinopathy and nephropathy in youth-onset compared with adult onset type 2 diabetes. Diabetes Care. 2003;26:76–81.

35.

Eppens

Craig

Cusumano

Prevalence of diabetes complications in adolescents with type 2 compared to type 1 diabetes. Diabetes Care. 2006;29:1300–1306.

36.

Dolan

Bean

Goodman

Frequency of abnormal carbohydrate metabolism and diabetes in a population-based screening of adolescents. J Pediatr. 2005;146:751–758.

37.

Duncan

Zhou

. Prevalence and trends of a metabolic syndrome phenotype among US adolescents, 1999–2000. Diabetes Care. 2004;27:2438–2443.

38.

Faraone

Biederman

Morley

Effect of stimulants on height and weight: A review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(9):994–1009.

Increased Prevalence of Obesity and Glucose Intolerance in Youth Treated with Second—Generation Antipsychotic Medications